Biogen (BIIB) Price Target Lifted to $422 at UBS Despite Caution on Tecfidera Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Biogen (BIIB) Weakness Overdone, Buy Pullback: BMO
April 24, 2015 3:32 PM EDTBMO Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $511. The stock dropped over 6% after the company reported Q1 results that missed consensus. In the view of analyst Jim Birchenough, weakness is overdone and represents a buying opportunity.
"We are reaffirming... More
Biogen (BIIB) Misses Q1 EPS by 6c; Revs Light
April 24, 2015 7:01 AM EDTBiogen (NASDAQ: BIIB) reported Q1 EPS of $3.82, versus the analyst estimate of $3.88. Revenue for the quarter came in at $2.56 billion versus the consensus estimate of $2.66 billion.
First Quarter 2015 Performance Highlights
Total multiple sclerosis product sales were $2.1 billion compared to $1.7 billion in the same quarter last year.TECFIDERA revenues... More